We simply coated the 14 Best Defensive Stocks to Invest In Now and Gilead Sciences, Inc. (NASDAQ:GILD) ranks 4th on this checklist.
Gilead Sciences, Inc. (NASDAQ:GILD) has transitioned away from its unstable COVID-19 remedy income from Veklury. The core enterprise in HIV and a rising oncology pipeline present the agency with high-visibility, non-discretionary earnings. The defensive power is the dominant place within the HIV market, which capabilities equally to a utility as a result of the remedies are life-sustaining and non-discretionary. Gilead’s HIV portfolio generated $20.8 billion in 2025. Sufferers not often swap remedies as soon as stabilized, making a extremely predictable money move that’s unaffected by broader financial cycles. In the course of the Barclays Healthcare Convention in March, CFO Andrew Dickinson emphasised that Gilead faces no main lack of exclusivity till 2036. This runway supplies a stage of security that’s uncommon within the pharma sector. Yeztugo, the primary twice-yearly HIV prevention remedy, is predicted to hit $800 million in gross sales in 2026.
READ MORE: 10 Best Stocks to Buy According to Billionaire Paul Tudor Jones.
Gilead Sciences, Inc. (NASDAQ:GILD) inventory is a favourite for income-focused funds due to its aggressive money return to shareholders. In February, the board raised the quarterly dividend to $0.82 per share, marking one other yr of consecutive progress. As of April, the ahead dividend yield stands at roughly 2.4%, backed by a wholesome non-GAAP EPS steering of $8.45–$8.85 for the complete yr. To bolster its defensive profile, Gilead has spent the final 5 years diversifying into oncology, which now accounts for about 12% of complete income. Merchandise like Trodelvy and cell therapies are seeing double-digit progress. This supplies a progress kicker on high of the defensive HIV base, diversifying the corporate’s danger throughout completely different therapeutic areas.
Whereas we acknowledge the potential of GILD as an funding, we imagine sure AI shares supply larger upside potential and carry much less draw back danger. In case you’re in search of a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the best short-term AI stock.
READ NEXT: Israel Englander Stock Portfolio: Top 10 Stock Picks and Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential.
Disclosure: None. Follow Insider Monkey on Google News.
